Researchers at the Mayo Clinic have developed a new blood test that could improve the detection of germ cell tumors, the most common type of testicular cancer. This method is designed to find cancers that are often missed by standard tumor marker tests.
The study introduced two tools based on immune system signals. One test, GCT-iSIGN, is used to detect cancer and showed high accuracy, identifying 93% of tumors and correctly ruling out cancer in 99% of healthy cases. It also detected most cases that traditional tests failed to find. The second test, Sem-iSIGN, helps distinguish between the main types of testicular cancer, which can guide treatment decisions.
This approach is important because some patients, especially younger ones, do not produce enough standard markers for early diagnosis. By analyzing immune patterns, researchers may enable earlier and more accurate detection.
Although the results are promising, more research is needed before these tests can be widely used in clinical practice.